Derivatives of human complement component C3 for therapeutic complement depletion: a novel class of therapeutic agents.

Abstract

To obtain proteins with the complement-depleting activity of Cobra Venom Factor (CVF), but with less immunogenicity, we have prepared human C3/CVF hybrid proteins, in which the C-terminus of the alpha-chain of human C3 is exchanged with homologous regions of the C-terminus of the beta-chain of CVF. We show that these hybrid proteins are able to deplete… (More)

Topics

  • Presentations referencing similar topics